Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

36 results about "Benzphetamine" patented technology

Benzphetamine is used short-term along with a doctor-approved, reduced-calorie diet, exercise, and behavior change program to help you lose weight. It is used in people who are significantly overweight (obese) and have not been able to lose enough weight with diet and exercise alone.

Abuse-resistant amphetamine prodrugs

The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Owner:TAKEDA PHARMA CO LTD

Abuse-resistant amphetamine prodrugs

InactiveUS7659253B2Reducing patient to patient variabilityRisk minimizationBiocideOrganic chemistryDiseaseChemical Moiety
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Owner:TAKEDA PHARMA CO LTD

Methods for treating an impairment in memory consolidation

InactiveUS7244769B2BiocideAnimal repellantsMemory consolidationL-Amphetamine
Impairments in memory consolidation are treated with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound. The method can include determining memory consolidation before, during and / or after administering the amphetamine compound.
Owner:COGNITION PHARMA LLC +2

Methods of enhancing selective serotonin reuptake inhibitor effects in mammals

The invention relates to methods of enhancing selective serotonin reuptake inhibitor effects in mammals. In particular, the invention provides methods for treating selective serotonin reuptake inhibitor dependent conditions such as depression. More specifically, the present invention relates to a method of increasing the antidepressant activity of a selective serotonin reuptake inhibitor (“SSRI”) by administering L-lysine-d-amphetamine in combination with an SSRI and to formulates containing the same. In a preferred aspect, the combination is administered in connection with a method of treating depression. One preferred SSRI is escitalopram. The preferred amphetamine prodrug is L-lysine-d-amphetamine.
Owner:SHIRE PLC

Amphetamine addict craving evaluation method

The invention relates to an amphetamine addict craving evaluation method. Craving of an amphetamine addict for amphetamines is induced by virtual reality technology, and whether craving of the addict for the amphetamines is induced successfully or not is evaluated by calculating objective data of heart rate variability of the addict. By the aid of the theoretical framework of conditioned reflex, most significant end multimedia information input is added and physiological signals are acquired based on psychology, relevant managers can conveniently evaluate the addict at regular intervals, and the recurrence possibility of the addict is maximally reduced.
Owner:杭州赛翁思科技有限公司

Methods for treating mild cognitive impairment and alzheimer's disease

Mild cognitive impairment and Alzheimer's disease are treated with an amphetamine compound. In one embodiment, the method includes administering an 1-amphetamine compound. In another embodiment, the method includes administering an 1-methamphetamine compound.
Owner:CNS ACQUISITIONS LLC

Andrographis Paniculata Compositions and Methods for Treatment of Addictions

Methods and compositions for the treatment or prevention of addictions and impulse control disorders using Andrographis paniculata, active substances contained therein and extracts thereof, alone or in combination with other therapeutic agents. The methods and compositions of the invention are useful in the treatment or prevention of addiction to substances, including alcohol, nicotine, marijuana, opioid agonists cocaine, and amphetamines, as well as impulse control disorders, including pathological gambling and pathological overeating.
Owner:OMEROS CORP

Methods and compositions for preparation of amphetamine conjugates and salts thereof

The invention provides methods and compositions for preparing amphetamine conjugates, such as lisdexamfetamine, homoarginine-D-amphetamine, and salts thereof. In one embodiment, the invention provides methods of preparing an amphetamine conjugate from a chloramphetamine intermediate.
Owner:CAMBREX CHARLES CITY INC

Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances

The invention discloses a medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances. The medicament is prepared from the following components by weight percent: 2-95% of antipsychotics, 0.001-5% of alpha2 adrenergic agonists, 0-5% of anticholinergic agent, 0-80% of nonopioid analgesic, and 0-10% of benzodiazepine. The pharmaceutical composition disclosed by the invention achieves an ideal effect when the symptoms of a sufferer abusing stimulants such as benzedrine, or abusing the opiates substances in a merging manner are treated; the withdrawal symptom can be rapidly and obviously controlled; the detoxification recovery rate can be up to over 90%.
Owner:卢正堂 +1

Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same

Disclosed are homoarginine amphetamine prodrug and / or conjugate compositions, salts thereof, or a combination thereof that can reduce or prevent amphetamine side effects in a human subject, and methods to reduce or prevent amphetamine side effects in a human subject.
Owner:SHIRE PLC

Application of candesartan in preparing methamphetamine addiction drugs

The invention relates to the application of candesartan in preparing methamphetamine addiction drugs, wherein the role of candesartan in treating the rewarding effect of amphetamines addiction behavior incentives is studied. The result of the study shows that, candesartan facilitates the fading of the rewarding effect of the addiction behaviors of mice addicted to amphetamines, and also greatly improves the learning and remembering ability of mice addicted to amphetamines during the water maze training process. Meanwhile, candesartan is capable of obviously regulating the temperatures of mice after taking amphetamines, and inhibiting the methamphetamine rewarding incentives of mice. Moreover, candesartan obviously inhibits the methamphetamine-induced spontaneous activity behaviors of mice. That means, candesartan can be used for the withdrawal of methamphetamine addiction behaviors and the development of novel anti-toxicant drugs.
Owner:NINGBO UNIV

Amphetamine Prodrugs

InactiveUS20140073589A1Inhibition spikesIncrease plasma concentrationBiocideNervous disorderAmphetamine useBenzphetamine
The present invention relates to amphetamine prodrugs which provide colonic release of amphetamine.
Owner:SHIRE PLC

Method for treating aspects of alcoholism, addiction and psychosis

This application relates to a method for treating various aspects of alcoholism, including alcohol craving and relapse into alcoholism, by the administration of an effective amount of gaseous anaesthesia to a deep surgical anaesthesia. The method can be applied for the alleviation of addiction and craving associated with amphetamine use, and for the alleviation of psychosis in schizophrenia and the alleviation of psychosis in Alzheimer's disease. In addition, the state of addiction or the state of psychosis, or the state of alcohol withdrawal can be monitored in animal tissue in vitro or in humans in vivo by measuring the density of the high-affinity states of the dopamine D2 receptors in the striatum or other brains regions containing these receptors which are elevated in these conditions.
Owner:SEEMAN PHILIP

Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome

The invention relates to a drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome, which comprises the following components in percent by weight: 2-95 percent of antipsychotics, 0.001-5 percent of a2 adrenergic receptor agonist, 0-5 percent of anticholinergic drug, 0-80 percent of non-opiates pain easing agent and 0-10 percent of benzodiazepines drugs. When used for treating symptoms occurring in patients abusing exhilarants of Benzedrine and the like or integrally abusing opioid, the drug achieves better effect, can rapidly and remarkably control abstinence syndrome, and has detoxification cure rate reaching over 90 percent.
Owner:卢正堂 +1

Phenoxypropylamine compounds

The present invention relates to a phenoxypropylamine compound of the formula (I)wherein each symbol is as defined in the specification, an optically active compound thereof or a pharmaceutically acceptable salt thereof and hydrates thereof, which simultaneously show selective affinity for and antagonistic activity against 5-HT1A receptor, as well as 5-HT reuptake inhibitory activity, and can be used as antidepressants quick in expressing an anti-depressive effect.
Owner:MITSUBISHI TANABE PHARMA CORP

Methods and compositions for preparation of amphetamine conjugates and salts thereof

The invention provides methods and compositions for preparing amphetamine conjugates, such as lisdexamfetamine, homoarginine-D-amphetamine, and salts thereof. In one embodiment, the invention provides methods of preparing an amphetamine conjugate from a chloramphetamine intermediate.
Owner:CAMBREX CHARLES CITY INC

Extract effective in treating drug addiction and preparation method therefor

Disclosed are an extract that is effective in treating drug addiction and a preparation method therefor. An effective component of the extract has the following chemical structural characteristics: a cholestenol compound with hydroxyl (OH) at position 3 and a double bond between position 5 and position 6, or a cholestenol compound with hydroxyl (OH) at position 3, a double bond between position 5 and position 6 and a double bond between position 22 and position 23. The extract can be extracted from the traditional Chinese medicine Agriolima agrestis. The extract of the present invention is safe in acute toxicity, sedative and hypnotic without physical and psychic dependence, has an inhibitory effect on excitability in mouse caused by morphine and benzedrine and a detoxification treatment effect on the withdrawal symptoms in morphine-dependent rats, and is useful in the development of medications or food for treating drug addiction.
Owner:GUANGXI JIUFU BIOTECH CO LTD

Assays for amphetamine and methamphetamine using stereospecific reagents

Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I may be employed in assays for the determination of an amphetamine and / or a methamphetamine. Immunogenic conjugates of Formula I may be employed to prepare antibodies for an amphetamine and / or for a methamphetamine for use in assays for the determination of an amphetamine and / or a methamphetamine. The enzyme conjugates may also be employed to screen antibodies for use in such methods.
Owner:SIEMENS HEALTHCARE DIAGNOSTICS INC

Extended release suspensions of mixtures of dextro- and levo-amphetamines

InactiveUS20190183817A1Eliminating complex and lengthy coating processGood masking effectPowder deliveryOrganic active ingredientsIn vivoBlood plasma
The present invention relates to the pharmaceutical compositions of a mixture of dextro- and levo-amphetamines complexed with ion exchange resin and precursor resins. More particularly the invention relates to Attention Deficit Hyperactivity Disorder (ADHD) effective agent dosage forms that both facilitate oral ingestion and provide an effective treatment over a prolonged period oftime. In particular, the invention provides for pharmaceutical compositions having a first and second plurality of particles, where the first plurality of particles comprises drug-resin particles and the second plurality of particles comprises drug-precursor resin particles with or without any extended release coating, where the drug is an ADHD effective agent and the composition achieves an escalating in vivo plasma concentration of the ADHD effective agents selected from amphetamine and methylphenidate.
Owner:LUPIN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products